Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression: an Unblinded Phase 1 Safety, Methodological and Exploratory Biomarkers Study.

NCT03887741 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03887741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03887741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression: an Unblinded Phase 1 Safety, Methodological and Exploratory Biomarkers Study.
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
September 15, 2021
Completion date
February 16, 2024
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment